To take advantage of live recombinant vesicular stomatitis viruses (rVSVs) as vaccine vectors for their high yield and for their induction of strong and long-lasting immune responses, it is necessary to make live vaccine vectors safe for use without losing their immunogenicity. We have generated safer and highly efficient recombinant VSV vaccine vectors by combining the M51R mutation in the M gene of serotype VSV-Indiana (VSV Ind ) with a temperature-sensitive mutation (tsO23) of the VSV Ind Orsay strain. In addition, we have generated two new serotype VSV-New Jersey (VSV NJ ) vaccine vectors by combining M48R and M51R mutations with G22E and L110F mutations in the M gene, rVSV NJ (G22E M48R M51R) [rVSV NJ (GMM)] and VSV NJ (G22E M48R M51R L110F) [rVSV NJ (GMML)]. The combined mutations G21E, M51R, and L111F in the M protein of VSV Ind significantly reduced the burst size of the virus by up to 10,000-fold at 37°C without affecting the level of protein expression. BHK 21 cells and SH-SY5Y human neuroblastoma cells infected with rVSV Ind (GML), rVSV NJ (GMM), and rVSV NJ (GMML) showed significantly reduced cytopathic effects in vitro at 37°C, and mice injected with 1 million infectious virus particles of these mutants into the brain showed no neurological dysfunctions or any other adverse effects. In order to increase the stability of the temperaturesensitive mutant, we have replaced the phenylalanine with alanine. This will change all three nucleotides from UUG (leucine) to GCA (alanine). The resulting L111A mutant showed the temperature-sensitive phenotype of rVSV Ind (GML) and increased stability. Twenty consecutive passages of rVSV Ind (GML) with an L111A mutation did not convert back to leucine (UUG) at position 111 in the M protein gene. 
IMPORTANCE

Recombinant vesicular stomatitis viruses as live vaccine vectors are very effective in expressing foreign genes and inducing adaptive T cell and B cell immune responses. As with any other live viruses in humans or animals, the use of live rVSVs as vaccine vec-
tors demands the utmost safety. Our strategy to attenuate rVSV Ind by utilizing a temperature-sensitive assembly-defective mutation of L111A and combining it with an M51R mutation in the M protein of rVSV Ind significantly reduced the pathogenicity of the virus while maintaining highly effective virus production. We believe our new temperature-sensitive M gene mutant of rVSV Ind (GML) and M gene mutants of rVSV NJ (GMM) and rVSV NJ (GMML) add excellent vaccine vectors to the pool of live viral vectors.
V esicular stomatitis virus (VSV) is a rapidly replicating virus.
Eventually humoral and cellular immune responses against VSV are elicited in the animal host, like any other viral vectors (1) (2) (3) . Animals infected with VSV develop immune responses within 2 weeks and start to neutralize the VSV (1) . This hinders the efficacy of boost immunizations for vaccination with the same vector. Serotype-specific antibodies against the viral surface glycoprotein G neutralize VSV. Two different serotypes of VSV, VSV-Indiana (VSV Ind ) and VSV-New Jersey (VSV NJ ), show 50% amino acid homologies in glycoprotein G (4) . Antibodies raised against one serotype of VSV do not neutralize the other serotype of VSV (5) . Accordingly, other investigators have used VSV Ind with its own surface glycoprotein G and VSV Ind carrying the G gene from other serotypes as a vaccine vector (6, 7) .
VSV causes self-limiting disease in animals such as pigs, cows, and horses, whereby vesicular lesions on the mouth, nose, teats, and hooves are cleared in a couple of weeks after the onset (8) .
Although it is very rare, human infections with VSV have been reported mostly in animal care workers, veterinarians, and laboratory personnel who were in close contact with the diseased animals or with the viruses (9) (10) (11) .
Safety concerns have been raised on the usage of VSV as a vaccine vector in humans because of the neurovirulence shown in nonhuman primates and young mice after intracerebral or intranasal inoculation (12) (13) (14) (15) . Any live viral vaccines for human use must pass the neurovirulence test in nonhuman primates (16) (17) (18) (19) . In order to take advantage of live rVSVs as a vaccine vector for their high yield and for their induction of strong and long-lasting immune responses, it is necessary to make the live vaccine vector safe to use in humans without losing its immunogenicity.
Efforts have been made to attenuate rVSV vectors to generate safer vaccine vectors. rVSVs with the G gene deleted (⌬G) and with single-cycle replication in regular cells and in the animal host were developed, and the ⌬G rVSV was amplified in the VSV G protein-expressing cell line (20) (21) (22) . This approach renders approximately a 2-log reduction of virus production, and it may produce inadequate quantities of virus for the preparation of live recombinant virus vaccines, should the vaccination require a high dose of virus. Another type of attenuated rVSV was generated by combining the deletion of the cytoplasmic tail of the G protein, gene translocation (especially the N gene to the 4th position), and noncytopathic M gene mutations with M33A and M51R (23, 24) . These mutations affected high-level virus production, since the attenuations were made by reducing replication efficiency and formation of virions.
VSV M protein induces cell death by blocking host cellular protein synthesis. Amino acid changes from methionine at position 51 (Met51) to arginine (Arg) in the VSV Ind M protein and changes of Met48 and Met51 to Arg in the VSV NJ M protein make the host cellular protein synthesis near normal (25, 26) . While VSVs with Met-to-Arg changes in the M protein have significantly reduced cytopathic effects (CPE), these viruses still replicate and produce progeny viruses in the cells and in the infected animal, maintaining their neurovirulence.
We sought a way to attenuate VSVs to maintain normal efficiency of viral replication in preparing a high-titer viral stock. We looked into temperature-sensitive (ts) mutants of VSVs, which cannot assemble or release infectious particles properly at a nonpermissive temperature (39°C) and also at a semipermissive temperature (37°C). One of the temperature-sensitive M gene mutants of the VSV Ind Orsay strain, the tsO23 mutant, has shown limited replication in a mouse glial cell line at 37°C and 39°C (27) . It has been demonstrated that the temperature sensitivity of the tsO23 mutant was the result of improper assembly or lack of initiation in viral assembly, with the characteristic bullet-shaped structure at 39°C (28, 29) . In addition, the original tsO23 mutant lost its neurovirulence in mice, as demonstrated by direct inoculation of the virus into the brain (27) .
Thus, we combined the M gene mutations, noncytopathic mutation with assembly-defective mutation tsO23 to attenuate the VSV Ind strain without negating viral production efficiency. We characterized some newly generated M gene mutants and found newly attenuated M gene mutants, VSV Ind (G21E M51R L111F) [rVSV Ind (GML)] or VSV Ind (G21E M51R L111A) [rVSV Ind (GML-New)] and two new M mutants of VSV NJ , rVSV NJ (G22E M48R M51R) [rVSV NJ (GMM)] and rVSV NJ (G22E M48R M51R L110F) [rVSV NJ (GMML)]. These new VSV M mutants were attenuated significantly and lost their neurovirulence but could still be used for induction of robust adaptive immune responses against inserted gene products.
MATERIALS AND METHODS
Cells.
Baby hamster kidney cells of the BHK 21 line (ATCC, CCL-10) were grown in Dulbecco's minimal essential medium (DMEM) (Invitrogen) containing 5% fetal bovine serum (FBS). Cells of the human neuroblastoma cell line SH-SY5Y (ATCC, CRL-2266) were maintained in a 1:1 mixture of Eagle's minimal essential medium (EMEM) (Sigma-Aldrich) and Ham's F-12 medium (Invitrogen) containing 10% FBS. Green monkey kidney cells of the Vero E6 line (ATCC, CRL-1586) were maintained in MEM (Invitrogen) containing 10% FBS and 1 mM sodium pyruvate. BSR T7/5 cells (30) were obtained from K. K. Conzelmann. The BHK 21 cells constitutively expressing bacteriophage T7 RNA polymerase were grown in DMEM containing 5% FBS and 500 g/ml G418 (Invitrogen).
Construction of plasmids. The full-length cDNA clone of VSV Ind was constructed from a VSV Ind heat-resistant (HR) strain. The cDNA from the leader region to the end of the P gene was synthesized by reverse transcription (RT) using primer Ind l (5=-ACGAAGACAAACAAACCAT TATT-3=). The double-stranded DNA from the leader region to the end of the P gene was synthesized by a two-step PCR. The PCR product with the restriction enzyme SapI site in part of the pTV vector (31) and the beginning of the leader region of the VSV Ind genome was first synthesized by using the primers Ind-l (5=-AATGATAATAATGGTTTGTTTGTCTTCG TCCTATAGTGAGTCGTATTAATTT-3=) and TV-Sap I (5=-CGGGCGG CCGCAAGCGGAAGAGCGCCCAA-3=). The first PCR product was used as a megaprimer for the amplification of the lNP region of the VSV Ind genome together with the primer Ind P(R) (5=-CGGGCGGC CGCCGGACCGTTAATTAACTACAGAGAATATTTGACTCTCGCCT-3=). The amplified PCR products were cloned into pBluescript II KS (pBKS) vector (Stratagene) at the NotI site (pBKS-Ind-lNP). The cDNAs from the intergenic junction in front of the L gene, the L gene, and the trailer region were also synthesized by reverse transcription using primer Ind-L(F) (5=-CGGGCGGCCGCGTTTAATTAACTCAAATCCT GCACAACAGA-3=), and the double-stranded DNA was synthesized by using primers Ind-L(F) and Ind t RsrII(R) (5=-CGGGCGGCCGCCGGAC CGCGAGGAGGTGGAGATGCCATGCCGACCCACGAAGACCA CAAAACCAGATAAA-3=). The PCR products were cloned into a pBKS vector at the NotI site (pBKS-Ind-Lt). The lNP region was cut from pBKSInd-lNP and cloned into pTV vector by using the SapI and RsrII sites in pTV (pTV-Ind-lNP). The Lt region was cut from pBKS-Ind-Lt by using restriction enzymes PacI and RsrII and cloned into pTV-Ind-lNP to construct the plasmid with the lNP and Lt regions of the VSV Ind genome (pTV-Ind-lNP/Lt). The cDNAs of the M gene and G gene region of VSV Ind were synthesized by reverse transcription, using the primer Ind M(F) (5=-TCCCCGCGGTTAATTAAACTATGAAAAAAAGTAACA GATATCACAATCTAAGTGTTATCCCAATCCATTCATCATGAGT TCCTTAAAGAAGATTCTC-3=) and was used for the synthesis of each double-stranded DNA of the M gene and G gene. The Ind M gene region was amplified by the PCR product using the primers Ind M(F) and Ind M(R) (5=-ATAGTTTAGCGGCCGCTAGACTAGCTCATTTGAAGTGG CTGACAGAAT-3=). The PCR product was cloned into pBKS by using SacII and NotI sites (pBKS-Ind M). The double-stranded DNA of the G gene region of VSV Ind was amplified by PCR using Ind G(F) (5=-ATAAGAATGCGGCCGCACTAGTTTTCTATCCCTATGAAAAAAAC TAACAGAGATCGATCTGTTTCCTTGACACCATGAAGTGCCTTTT GTACTAGCTT-3=) and Ind G(R) (5=-GCTCTAGATTAATTAAAC TAGTGGTACCTTACTTCCCAAGTCGGTTCATCT-3=). The PCR product of the G gene region was cloned into the pBKS vector by using the NotI site and XbaI site (pBKS-Ind G). The M gene region and G gene region were combined in the pBKS vector using the NotI and XbaI sites (pBKS-Ind MG). PacI sites were introduced into the beginning and the end of the M and G gene regions, and a NotI site was introduced between the M gene and G gene. The combined M and G gene region was cut from the pBKS-Ind MG with the restriction enzyme PacI and cloned into the pTV-Ind-lNP/Lt to construct the full-length DNA clone of VSV Ind (prVSV Ind ). More unique restriction enzyme sites PmeI, XhoI, and MluI were added into the untranslated region at the end of the G gene in prVSV Ind by inserting a double-stranded DNA linker of Ind-PXM(1) (5=-TAAGTTTAAAGCCTCGAGATACGCGTTTAAT-3=) and Ind-PXM(2) (5=-TAAACGCGTATCTCGAGGCGTTTAAACTTAAT-3=) into the PacI site. The resulting plasmid was named prVSV Ind (WT). Mutations in the VSV Ind M gene were introduced by the megaprimer PCR method. The double-stranded DNA megaprimer with mutation was synthesized by the PCR using prVSV Ind (WT) as a template and as a forward primer IMM(F) (5=-GGGCTCGAGTACAAAAAGTTGTACAATCAGGCGAG-3=) and one of the mutagenic primers of IM(M51R) (5=-CATGAGTGTC CCTCTCGTCAACT-3=) or IM(G21E) (5=-GGTGCGATTTCTAATTTC TTAGATTTC-3=). The first PCR product was used together with the primer IMM(R) (5=-CTTCATGGTGTCAAGGAAACAG-3=) to synthesize the full-length rVSV Ind M gene with the G21E mutation or M51R mutation. The PCR product was cut with PacI and NotI and replaced the M gene of prVSV Ind . The resulting plasmids were prVSV Ind (G21E) and prVSV Ind (M51R). The mutagenic primer IM(M51R) and the template prVSV Ind (G21E) were used to construct prVSV Ind (G21E M51R) [prVSV Ind (GM)]. The mutagenic primer IM(L111F) (5=-TAGAAGAAC CAAAAAAAGCCAAG-3=) was used for the PCR with the template prVSV Ind (G21E) to construct prVSV Ind (G21E L111F) [prVSV Ind (GL)]. prVSV Ind (G21E M51R L111F) [prVSV Ind (GML)] was generated by introducing mutations with the mutagenic primer IM(L111F) and prVSV Ind (GM) as a template. prVSV Ind (GML)-New was generated by a two-step cloning process. First, the codon for arginine at 51R in the M protein of the rVSV Ind (GML) was changed to CGA. In order to change the codon to CGA, we used the forward primer IMM(F) and the mutagenic primer IM(M51R-CGA) (5=-CATGAGTGTCTCGCTCGTCAACT-3=) and prVSV Ind (GML) as a template for the first PCR product. The first PCR product was used as a megaprimer together with the reverse primer IMM(R) to synthesize the full-length M gene with the codon change at 51R. The second codon change at F111 was introduced by changing phenylalanine (TTT) to alanine (GCA). The F111A mutation in the M gene was generated by using the forward primer IMM(F), the reverse primer IMM(R), and the mutagenic primer IM(L111A) (5=-AGAAGAACCTGC AAAAGCCAAGATC-3=).
We added more unique restriction enzyme sites at the junction of the G gene and L gene of prVSV NJ (WT) (26) . Unique restriction enzyme sites FseI, PmeI, XhoI, and MluI were added by inserting the double-stranded DNA linker of NJ-FPXM(1) (5=-CGGCCGGCCATGTTTAAACCACTC GAGATACGCGTGGTAC-3=) and NJ-FPXM(2) (5=-CACGCGTATCTC GAGTGGTTTAAACATGGCCGGCCGGTAC-3=) into the G gene and L gene junction at the KpnI site of prVSV NJ (WT). The mutation G22E was introduced into the M gene of VSV NJ (WT) by the megaprimer PCR method using the forward primer NJMM(F) (5=-GGGCTCGAGAGACT TGATGGGAGCAATCATCATG-3=) and mutagenic primer NJM(G22E) (5=-GAGGTGGCAATTCTAGTTTCTTTGAT-3=). The full-length DNA of the VSV NJ M gene with the G22E mutation was synthesized by using the first PCR product with the mutation and reverse primer NJMM(R) (5=-C CACCATTGCAAGAATTAGATAAGACAA-3=). The PCR product with the mutation was cut with PacI and NotI and replaced the wild-type (WT) M gene in the prVSV NJ (WT) to generate prVSV NJ (G22E). By the same method, we generated prVSV NJ (G22E M48R M51R) [prVSV NJ (GMM)], prVSV NJ (G22E L110F) [prVSV NJ (GL)], and prVSV NJ (G22E M48R M51R L110F) [prVSV NJ (GMML)]. prVSV NJ (GMM) was constructed by using prVSV NJ (M48R M51R) as a template and the mutagenic primer NJM(G22E). prVSV NJ (GL) was constructed by using prVSV NJ (G22E) as a template and NJM(L110F) (5=-GGAGCCAATAAAAGCAATTATC-3=) as a mutagenic primer. prVSV NJ (GMML) was constructed by using prVSV NJ (GMM) as a template and NJM(L110F) as a mutagenic primer. prVSV NJ (GMM)-New was constructed by using prVSV NJ (GMM) as a template and the mutagenic primer NJM(M48R M51R-CGT) (5=-TATC ATATAAATCTCGATCCTCTCGTCCGAAGAAGTCA-3=).
Recovery of rVSV by reverse genetics and the preparation of viral stocks. Recombinant VSVs were recovered by reverse genetics as described previously (26) . The recombinant wild-type and M gene mutants of rVSV were recovered from the plasmids of full-length genomic clones of rVSVs: prVSV Ind (WT), prVSV Ind (M51R), prVSV Ind (G21E), prVSV Ind (GM), prVSV Ind (GL), prVSV Ind (GML), prVSV NJ (WT), prVSV NJ (M48R M51R), prVSV NJ (G21E), prVSV NJ (GMM), prVSV NJ (GL), prVSV NJ (GMML), prVSV Ind (GML)-New, and prVSV NJ (GMM)-New. BSR T7/5 cells were cotransfected with the full-length genomic cDNA clones of rVSV and three other plasmids expressing the nucleocapsid protein (pBKS-IRES/N NJ ), phosphoprotein (pBKS-IRES/P NJ ), and VSV polymerase L protein (pBKS-IRES/L NJ ) in concentrations of 10 g of pN, 10 g of pP, 5 g of pL, and 15 g of prVSV.
The newly generated rVSVs were purified three consecutive times by plaque picking, and were amplified for a larger volume of stock viruses by infecting BHK 21 cells at a virus multiplicity of infection (MOI) of 0.1 at 31°C.
Viral preparation and titration.
The plaque-picked viruses were first amplified in a small-scale 2-ml culture of BHK 21 cells, and the viruses were titrated using a monolayer culture of Vero E6 cells by plaque assay. The cells infected with the mutant viruses for the plaque assay were incubated at 31°C. For a larger viral stock, BHK 21 cells were infected with a virus MOI of 0.1 and incubated at 31°C, and the culture medium was harvested at 20 h postinfection.
Determination of protein expression. In order to examine the expression of VSV proteins, we analyzed 5 g of cell lysate of infected cells by SDS-PAGE, and the proteins were transferred to the polyvinylidene difluoride (PVDF) membrane (Immobilon; Millipore). The VSV proteins were detected by Western blotting using ECL Plus enhanced chemiluminescence Western blotting detection reagents (Amersham Biosciences). VSV proteins were detected by using rabbit serum against total protein of VSV (32) .
Determination of cell death. Death of the infected cells by rVSV infection was measured by detecting the release of lactate dehydrogenase (LDH) from the damaged cells using a cytotoxicity detection kit (Roche). The infected cells were maintained in an appropriate culture medium with 1% FBS to minimize the detection of LDH from the FBS. Culture medium from the infected cells was collected at 8 h postinfection, 100 l of the culture medium was added to a 96-well plate, and then 100 l of reaction mixture (diaphorase-NAD ϩ mixture with iodotetrazolium chloride and sodium lactate) was added. The mixture was incubated for 30 min at room temperature. The absorbance of the samples was measured at a 490-nm filter setting using an enzyme-linked immunosorbent assay (ELISA) reader (model 550; Bio-Rad).
Neuropathological study in mice. We used 7-week-old Swiss Webster mice from the Charles River Laboratory, which were implanted with an intralateral ventricular cannula (IVC) into the brain. The mice were anesthetized with ketamine (1.0 mg/10 g) and xylazine (0.1 mg/10 g) before injection. The mice were injected with viruses 1 week after arrival at the animal facility. The mice were injected with 1 ϫ 10 3 or 1 ϫ 10 6 PFU of viruses in 5-l inoculums diluted with a serum-free DMEM. A sterile microsyringe with a 10-l volume (Hamilton) was connected to a small piece of sterile polyethylene tubing (PE50; Becton Dickinson) to fit into the IVC. The syringe was mounted onto the manual sterotaxic injector (Stoelting), and the 5-l volume of inoculum was injected into the brain over 15 min. The rVSV-injected mice were observed for neurological dysfunction and weighed every day for a month. Animal care and procedures were compliant with the guidelines of the Animal Care and Use Committee of the University of Western Ontario.
RT-PCR. Genomic RNA of the rVSV was isolated from the concentrated viruses by using the QIAamp viral RNA minikit (Qiagen). The cDNAs of the M gene of the old and new rVSV Ind (GML) strains were synthesized by RT-PCR using primers IP2101F (5=-GAGGTAACGGA CGAATGTCT-3=) and IL3160R (5=-AATCTGAGCTTGACGGGCAA-3=). The cDNAs of the M gene of the old and new rVSV NJ (GMM) strains were synthesized by RT-PCR using primers H1F (5=-ACGAAG ACAAAAAAACCATTCTTAC-3=) and H3100R (5=-AAGAGTATTAA AGCGGCCGCTT-3=).
RESULTS
Addition of assembly-defective ts mutations into the M genes of rVSV Ind and rVSV NJ . There are three amino acid changes in the M protein of the VSV Orsay tsO23 mutant strain, which are the glycine-to-glutamic acid change at the 21st amino acid (G21E), the leucine-to-phenylalanine change at the 111th amino acid (L111F), and the histidine-to-tyrosine change at the 227th amino acid (H227Y) (33) . The single-amino-acid reversion at F111 to L implied that F111 has a major role in the temperature sensitivity of the tsO23 mutant, resulting in retarded assembly and release of VSV particles at a nonpermissive temperature of 39°C (33) . Therefore, we introduced the L111F mutation into the M gene of rVSV Ind together with the G21E mutation or G21E and M51R (Fig. 1A) . The methionine-to-arginine change at the 51st amino acid (M51R) in the M protein, which reduces the inhibitory activity of the M protein on cellular protein synthesis, was combined with the G21E and L111F mutations in order to further attenuate the virulence of VSV Ind .
The amino acids G21 and L111, which we changed to E and F, respectively, in the M protein of VSV Ind , are not present at the exact positions in the M protein of VSV NJ but there are G22 and L110, which are close to the G21 and L111 of rVSV Ind M. Therefore, we changed G22 to E and L110 to F in the rVSV NJ M protein.
As with the VSV Ind mutants, to further attenuate the virulence of VSV NJ , we combined the mutations G22E and L110F with the M48R and M51R mutations of rVSV NJ , which shows reduced inhibitory effects of the M protein on host cellular protein synthesis (Fig. 1B) .
Wild-type and mutant rVSV Ind and rVSV NJ were recovered from the cDNA plasmids by reverse genetics, as described in Materials and Methods. The transfected BHK-T7 cells for the recovery of rVSV ts M mutants were incubated at 31°C, and the culture medium was collected when the CPE showed, which took approximately 4 to 5 days posttransfection.
The mutation L111F in the M protein significantly reduces the burst size of rVSV Ind at a semipermissive temperature of 37°C. In order to examine the effect of L111F mutation on the release of the virus particles from the infected cells, we first checked the burst sizes of the new M mutants and compared them to that of the wild-type rVSV Ind strain. First, the burst sizes of the viruses were determined in BHK 21 cells at 10 h postinfection with a virus MOI of 3 at both permissive (31°C) and semipermissive (37°C) temperatures. The rVSV Ind (GL) and rVSV Ind (GML) mutants produced 100-fold less infectious virus particles at 37°C than at 31°C, demonstrating the temperature sensitivity of the mutants in the release of virus particles at 37°C (data not shown). Then we examined the kinetics of infectious virus production of the M mutants during the course of 10 h of incubation at 31°C and 37°C. The neurovirulence shown in mice by VSV injection intranasally, intracranially, or intravenously (27) prompted us to examine the replication of the mutant VSVs in the human neuroblastoma cell line SH-SY5Y. We infected BHK 21 cells and SH-SY5Y cells with wild-type and M mutant rVSVs at an MOI of 3 in order to infect every cell with at least one infectious particle. The infected cells were incubated at a permissive temperature (31°C) and at a semipermissive temperature (37°C), and culture medium from the infected cells was collected every 2 h until 10 h postinfection. The number of infectious viral particles in the culture medium was determined by plaque assay at 31°C using Vero E6 cells. The wildtype virus and all mutant viruses replicated equally well at 31°C and produced similar titers of infectious viruses throughout the 10 h of incubation ( Fig. 2A and C) . However, the M mutants of rVSV Ind with L111F, rVSV Ind (GL) and rVSV Ind (GML), replicated with significantly lower titers-as much as 3 to 4 orders of magnitude lower during the course of infection than wild-type or M51R mutants of rVSV Ind at 37°C (Fig. 2B and D) . This demonstrated that the L111F mutation has a key role in impaired VSV particle production at 37°C. rVSV Ind (GML) produced the smallest amount of infectious particles along the course of infection in both BHK 21 cells and SH-SY5Y cells at 37°C. The differences in production of infectious particles between the wild type and rVSV Ind (GML) were as large as 4 logs at 6 h postinfection ( Fig.  2B and D) .
Mutations in the M protein of rVSV NJ G22E and L110F are not temperature sensitive in viral production at 37°C. The temperature sensitivities of the newly generated M mutants of rVSV NJ were examined by infecting BHK 21 The mutations in the M gene were introduced by site-directed mutagenesis using the megaprimer PCR method, and the PCR products were cloned into PacI and NotI sites to replace the wild-type M gene in both rVSV Ind and rVSV NJ . The format used shows the original amino acid before the number followed by the mutated amino acid after the number. M; methionine, R; arginine, G; glycine, E; glutamic acid, L; leucine, F; phenylalanine.
incubated at 37°C and 31°C, and the culture medium was harvested at 10 h postinfection to examine the burst size of the viruses. The wild type and all M mutants of rVSV NJ replicated equally well at 31 and 37°C (Fig. 2E) , indicating that the introduction of G22E and L110F mutations into the M protein of rVSV NJ did not affect the assembly and release of the virus at 37°C. Although the mutations G22E and L110F did not make VSV NJ temperature sensitive, the VSV NJ mutant with the M48R and M51R mutations alone or together with G22E (GMM) and L110F (GMML) produced less infectious VSV NJ by half a log to 1 log versus wild-type rVSV NJ .
Assembly defectiveness at a semipermissive temperature by the L111F mutation in the M protein of rVSV Ind does not affect the expression of VSV proteins. In order for the rVSV to be used as a vaccine vector, the virus should express genes of interest well, and the temperature sensitivity of M gene mutants should not reduce gene expression. Because the mutations we introduced were intended to make VSV assembly defective at a semipermissive temperature without affecting genome replication or transcription of VSV, the levels of viral protein expression at both temperatures should be similar in cells infected with enough viruses to infect all cells. Therefore, we infected BHK 21 cells with both wild-type and M gene mutants of rVSV Ind and rVSV NJ at an MOI of 6. The infected cells were incubated at both 37°C and 31°C for 6 h. The infected cells were lysed at 6 h postinfection, 5 g of total protein was analyzed using SDS-PAGE, and rVSV proteins were detected by Western blotting using rabbit antiserum against VSV Ind or VSV NJ . The result showed that in spite of the mutations that reduced the burst size of the rVSVInd at 37°C (L111F in the G21E L111F and G21E M51R L111F combined mutations), the level of VSV protein expression was the same as that of the wildtype rVSV Ind (Fig. 3A) when each cell was infected with at least two infectious particles at an MOI of 6. The wild type and all M mutants of rVSV NJ expressed their proteins at similar levels at both 31 and 37°C (Fig. 3B) .
Combined mutations G21E M51R L111F in the M protein of rVSV Ind and G22E M48R M51R and G22E M48R M51R L110F in the M protein of rVSV NJ reduced cytopathogenicity significantly in BHK 21 cells and in SH-SY5Y human neuroblastoma cells.
The typical cytopathic effects caused by the VSV are the rounding-up and lysis of infected cells (34) . The mutations we introduced in rVSV made the rVSV defective in the assembly and release of the virus, and the defect would retard the spread of rVSV to the neighboring cells. The result is reduced overall cell death and damage to the cells over time. Extracellular lactate dehydrogenase (LDH) activity was measured to detect cell damage, which was released from the infected cells and induced by various causes (35) (36) (37) (38) . In order to examine the effects of mutations L111F and M51R of the M protein of rVSV Ind on cytopathogenicity, we infected BHK 21 cells and SH-SY5Y cells with rVSV Ind at an MOI of 6 and incubated them at 37°C. At 8 h postinfection, the culture medium was collected to measure the LDH activity, which indicates cellular damage caused by the rVSV infection. In BHK 21 cells, GL and GML mutants of rVSV Ind caused the least cytolysis, in which LDH activity was slightly higher than that of the uninfected cell control (Fig. 4A) . The GML mutant of rVSV Ind showed the least cytolysis in SH-SY5Y cells (Fig. 4C) , indicating that the combined mutations of M51R and L111F in the M protein of rVSV Ind have the greatest effect on viral assembly, release of the viruses, and overall cell death.
All of the rVSV NJ mutants showed reduced cytolysis of the infected cells compared to the wild-type rVSV NJ in both BHK 21 cells and SH-SY5Y cells (Fig. 4B and D) . Among the rVSV NJ mutants, the GMM and GMML mutants caused the least cell damage in both BHK 21 and SH-SY5Y cells (Fig. 4B and D) . In the SH-SY5Y cells, the rVSV NJ GMM and GMML mutants caused cell damage similar to or less than that in the uninfected cells (Fig. 4D) . The result of using rVSV NJ mutants indicated that combined mutations of G22E and M48R M51R in the M protein made the virus less cytolytic in BHK 21 cells and SH-SY5Y cells.
In order to examine the effects of the mutations of L111F and M51R of the M protein of rVSV Ind on virus release and subsequent overall cytopathic effects, we infected BHK 21 and SH-SY5Y cells with rVSV Ind at an MOI of 0.1: this infected less than 1 in 10 cells (Fig. 5A and B) . The cytopathic effects caused by the rVSV Ind (GML) was compared with those of the other mutants of rVSV Ind . At 20 h of infection, rVSV Ind (GML) showed the most reduced cytopathic effects at 37°C, and the combination of mutations L111F and M51R (Fig. 5A-14 and B-12) further attenuated the cytopathogenicity of the virus versus the single mutation of each in both BHK 21 and SH-SY5Y cells.
In order to examine the effects of the mutations G22E, L110F, and M48R M51R of the M protein of rVSV NJ on cytopathogenicity, we infected BHK 21 and SH-SY5Y cells with rVSV NJ at an MOI of 0.1. At 20 h postinfection, we compared the cytopathic effects caused by the rVSV NJ wild type and M mutants. The GMM and GMML mutant showed the most reduced cytopathic effects at 37°C, and the combination of the mutations G22E and M48R M51R further attenuated the cytopathogenicity of the rVSV NJ in both BHK 21 (Fig. 6A-12 and A-14) and SH-SY5Y cells (Fig. 6B-12 and B-14).
rVSV Ind with the mutations G21E M51R L111F and rVSV NJ with the mutations G22E M48R M51R and G22E M48R M51R L110F in the M protein were attenuated to the degree that mice injected with these viruses into the brain showed no adverse neurological signs or symptoms. VSV does not show neurotropism in naturally infected animals through skin abrasion or sand fly or mosquito bites (8, 39) . Nevertheless, when wild-type VSV is injected directly into the nose or brain of mice or monkeys, the animals demonstrate adverse neurological symptoms (12, 15, 27) . In order to examine the neurovirulence of the new M mutants of VSVs, we injected 7-week-old Swiss Webster mice with 1 ϫ 10 6 PFU of mutant VSV and 1 ϫ 10 3 PFU of wild-type VSV into the intralateral ventricle of the brain. After viral injection, mice were observed for neurological dysfunctions and were weighed every 2 days for 4 weeks. The mice injected with 1 ϫ 10 3 PFU of wild-type rVSV Ind died within 4 days postinjection (Fig. 7A) . Two mice injected with 1 ϫ 10 6 PFU of rVSV Ind (M51R) (Fig. 7C ) lost about 20% of their body weight 6 days after injection. Their body weight bounced back to normal at about 14 days postinjection. One mouse injected with the rVSV Ind (M51R) mutant did not lose its body weight through the experiment. All three mice injected with rVSV Ind (GML) showed no sign of illness and did not lose their body weight for 4 weeks (Fig. 7D) , indicating the combination of mutations G21E, M51R, and L111F significantly attenuated rVSV Ind , and it lost its neurovirulence in mice. One mouse injected with rVSV NJ (WT) showed paralysis in both hind legs and was sacrificed on day 6 postinjection (Fig. 7E) . Two other mice injected with rVSV NJ (WT) and three mice injected with rVSV NJ (M48R M51R), rVSV NJ (GMM), or rVSV NJ (GMML) showed no sign of illness or weight loss during the 4 weeks following injection (Fig. 7F, G, and H) . These results show clearly that mutations in the rVSV Ind (GML), rVSV NJ (GMM), and rVSV NJ (GMML) strains changed their neurovirulence to levels where there were no adverse neurological signs or symptoms.
Further nucleotide changes increase the stability of the temperature-sensitive mutations of L111F in the M gene of rVSV Ind (GML) at 31 and 37°C. Temperature-sensitive mutants can be reverted to wild-type VSV when the infected cells are passaged many times at 37°C or 39°C. Our ts M mutants only had one or two nucleotide changes in the codon (underlined), such as from GGG to GAA for G21E, from AUG to AGG for M51R, from UUG to UUU for L111F in the M gene of rVSV Ind; from GGC to GAA for G22E, and from AUG to AGG for M48R and M51R in the M gene of rVSV NJ . In order to prevent the possible reversion of the ts mutants, we changed all three nucleotides in the codons for M51R and L111F in the M gene of rVSV Ind (GML) and all three codons for amino acid changes of M48R and M51R in the M gene of rVSV NJ (GMM). The arginine codon, AGG, was further changed to CGU in M51R, and phenylalanine codon, UUU, was changed to GCA for alanine in L111F in the M gene of rVSV Ind (GML). The arginine codon, AGG, was changed to another arginine codon, CGU, in the M48R and M51R mutations of rVSV NJ (GMM) M protein. The ts mutants of the new rVSV Ind (GML) and the new rVSV NJ (GMM) mutant with all nucleotide changes were recovered from the DNA plasmid. First, the temperature sensitivity of the newly constructed rVSV Ind (GMM) and rVSV NJ (GMM) was examined by determining the growth kinetics of the viruses. BHK 21 cells were infected with a virus MOI of 3, and the culture medium was collected every 2 h until 10 h postinfection. Both old and new rVSV Ind (GML) and rVSV NJ (GMM) mutants replicated with the same growth kinetics, and the change of phenylalanine to NJ . P values (*, **, and ***, P Ͻ 0.05) were computed by using a two-sided independent sample t test. The error bars represent the standard deviation of the mean. The horizontal lines on the graph represent the background level of LDH activity from the uninfected cells.
alanine in the L111A mutation of rVSV Ind M maintained the temperature sensitivity of the new rVSV Ind (GML) mutant (Fig. 8A) .
We compared the stabilities of the mutations of the ts M gene mutants of rVSV Ind and rVSV NJ (GMM) between old and new viruses at 31 and 37°C. The stability of the mutation was examined after 20 consecutive passages of the viruses at 37°C. BHK 21 cells were initially infected with an MOI of 0.1 of old and new M gene mutants of rVSV Ind and rVSV NJ . After 18 h of incubation, the culture medium containing viruses was collected, and fresh BHK 21 cells were infected with the collected viruses for additional viral passages at 31 and 37°C. At the 20th passage, the infectious viral titer was determined by plaque assay, and the fresh BHK 21 cells were infected with a virus MOI of 0.1 on the 20th passage of the old and new rVSV Ind (GML) and rVSV NJ (GMM) viruses. The rVSVs from 30 ml of the culture medium from the infected cell culture were concentrated and were resuspended in 1 ml of phosphate-buffered saline. The cDNAs of the M genes of the old and the new rVSV Ind (GML) and rVSV NJ (GMM) viruses were synthe- sized by RT-PCR. Double-stranded DNA of the complete M gene was sequenced. There were no nucleotides that changed back to wild-type codons for G21E and M51R in the M genes of both the old and new rVSV Ind (GML) mutants at both 31 and 37°C (Table 1) . However, the phenylalanine codon, UUU, was changed back to CUU for leucine at L111F in the M gene of the old rVSV Ind (GML) mutant after 20 consecutive passages of the viruses at 31°C and 37°C (Table 1) . When the phenylalanine codon, UUU, was changed to the alanine codon, GCA (L111A), the alanine was not changed back to leucine or any other amino acid (Table 1 ). These results demonstrate that all three nucleotide changes and an amino acid change from L111F to L111A kept the temperaturesensitive phenotype of rVSV Ind (GML) at 37°C and increased the stability of the mutation L111A at both 31 and 37°C with continuous passages. Because the mutations in the M gene of rVSV NJ (GMM) were not temperature sensitive, we expected 
DISCUSSION
Since VSV was developed as a viral vaccine vector, it has been demonstrated that VSV could induce good cellular and humoral immune responses against foreign genes (6, 23, (40) (41) (42) . Because of its ability to infect most mammalian cells and to induce immune responses, the use of the VSV as a vaccine vector for various human pathogens is increasing. However, the foremost concern for rVSV use as a vaccine vector is its safety. All attenuated live viral vaccines, including rVSVs, for human use have to go through stringent procedures to prove that they are safe to use in humans. Therefore, various strategies have been developed to attenuate the rVSVs to have reduced virulence. Attenuation of rVSV was accomplished by reducing the cytopathic effects of the M protein with mutations such as M51R in rVSV Ind (41, 43) and M48R M51R in rVSV NJ (26, 44) . The M51R mutation alone in the M gene of rVSV Ind reduced cytopathogenicity of VSV, but it was not attenuated enough to be nonneurovirulent in vitro and in mice (24) (Fig. 4 and 5C) . The G gene modifications in the rVSV genome, such as complete deletion of the gene (21) or partial deletion of the cytoplasmic tail region of the gene, were applied to attenuate the VSV (24, 45) . Rearrangement of VSV genes, especially N gene translocation, was also used to attenuate the VSV (24, 46) . These methods of VSV attenuation reduce the replication ability of rVSVs (24) and, inadvertently, the viral yields as well when viral stocks were prepared in vitro.
Because of the neurovirulence observed in animals injected intranasally or intracranially with rVSVs, researchers have been putting a lot of effort into making rVSVs as safer vaccine vectors. We have also been working on developing a safe rVSV as a vaccine vector. Our strategy was to use temperature-sensitive VSV strains that do not produce virus particles but have normal genome replication and gene transcription at a semipermissive temperature (37°C). In order to develop rVSVs where neurovirulence is attenuated at a normal body temperature but maintains productivity in vitro, we looked for ts mutants of the VSV M gene. One of the ts mutants was the tsO23 mutant of the Orsay strain of rVSV Ind , which showed assembly defectiveness at semipermissive (37°C) and nonpermissive (39°C) temperatures (27, 33) . We introduced mutations (single or combined mutations) of tsO23 into the M gene of our prVSV Ind (HR strain) and prVSV NJ Hazlehurst strain, as depicted in Fig. 1 . The combined mutations G21E M51R L111F in the M gene of rVSV Ind and G22E M48R M51R and G22E M48R M51R L110F in the M gene of rVSV NJ showed the least cytopathic effects in vitro and nonneurovirulence in mice.
There have been several mutations found in the M gene of the tsO23 strain. It was suggested that the L111F mutation in the tsO23 strain was the key mutation that might have given the tsO23 mutant the phenotypic characteristics at a nonpermissive temperature (33) . In both baby hamster kidney cells and human neuroblastoma cells, the rVSV Ind strains with L111F mutation, rVSV Ind (GL) and rVSV Ind (GML), showed significantly lower viral production through the course of infection at 37°C (Fig. 2B and  D) . The rVSV Ind strain with a G21E mutation showed the same growth kinetics as the wild type and the M51R mutant of rVSV Ind at 31 and 37°C. However, when the L111F mutation was added to G21E to make the G21E L111F double mutant, the mutant became temperature sensitive at a semipermissive temperature (37°C). Thus, this indicated that L111F is the key mutation for temperature sensitivity. In addition, when M51R was added to the G21E L111F mutation to generate rVSV Ind with G21E M51R L111F mutations, the combined mutations reduced the growth rate of the rVSV Ind by 5-to 10-fold ( Fig. 2B and D) . This is the same as the cytopathogenicity induced by the rVSV Ind mutants, which is shown in Fig. 5A-13, A-14, B-11, and B-12 . The addition of L111F and M51R mutations to G21E further decreased cytopathogenicity in BHK 21 cells and human neuroblastoma cell lines. The overall reduced cytopathogenicity in vitro was confirmed by the reduced LDH secretion from both BHK 21 cells and SH-SY5Y cells infected with rVSV Ind (GML). Other attenuated rVSVs were generated by moving the N gene to other locations, by deleting various numbers of amino acids in the cytoplasmic tail of the G protein, and by placing a gene of interest as the first gene to be expressed (23, 24) . These strategies of attenuation disrupted the stoichiometry of VSV proteins and assembly of the VSV, resulting in significant reduction of VSV production by 100-fold to 1,000-fold less than that of the wild-type VSV (24) . An unwanted outcome of this strategy is significant reduction of the VSV yields in vitro for vaccine preparation. Our strategy to attenuate the VSV by introducing assembly-defective temperature-sensitive mutations in the M gene of VSV Ind generated the vaccine vector without affecting genome replication and gene expression in the infected cells at both permissive (31°C) and semipermissive (37°C) temperatures. Importantly, the assembly of the VSV is not affected at 31°C, and the rVSV Ind (GML) mutant could be prepared in a high titer in vitro at 31°C. L111 in the VSV Ind M protein is located at the alpha-helix region in which the amino acid is surrounded by hydrophobic amino acids (47) . It has been suggested that the L111F mutation in the M protein of VSV Ind aggregates M protein on the cytoplasmic membrane and prevents the initiation of nucleocapsid-M protein complex formation (28) for the assembly of VSV particles at a nonpermissive temperature (39°C). Leucine is not present exactly at the same 111th position in the M protein of VSV NJ , but it is found at the 110th position. The M proteins of both VSV Ind and VSV NJ are 229 amino acids long. Because of the closeness of the leucine in the M protein of VSV NJ to the L111 of the VSV Ind M 
protein, we changed the leucine to phenylalanine at the 110th position of the VSV NJ M protein with the expectation of having the same temperature sensitivity of VSV NJ as that of VSV Ind . However, the L110F mutation in the rVSV NJ M protein did not make the rVSV NJ mutant temperature sensitive at a semipermissive temperature (37°C), and rVSV NJ strains with the L110F mutation, such as rVSV NJ (GL) and rVSV NJ (GMML), produced similar levels of infectious rVSV NJ at both 31 and 37°C (Fig. 2E) . Therefore, the mutation is either irrelevant to the temperature sensitivity of virus particle assembly in VSV NJ or the 111th isoleucine in the VSV NJ M protein, which is as hydrophobic as leucine at the same position as the L111 of VSV Ind M, may be important for the assembly of the VSV NJ . The I111F mutation in the VSV NJ M protein needs to be tested to see if it makes VSV NJ assembly defective at 37 and 39°C. The G22E and L110F mutations in addition to the M48R M51R double mutation did not make rVSV NJ assembly defective at 37°C. However, when we checked the cytopathogenicity of the mutants in BHK 21 cells and SH-SY5Y cells, the combined mutations G22E M48R M51R (GMM) and G22E M48R M51R L110F (GMML) reduced cytopathic effects most significantly at 37°C. The cytopathic effects in vitro by rVSV NJ (GMM) and rVSV NJ (GMML) were attenuated mainly by the presence of the M48R and M51R mutations in BHK 21 cells and SH-SY5Y cells (Fig. 6A-8 and B-8).
The addition of the G22E mutation in rVSV NJ (GMM) and the addition of G22E and L110F mutations in rVSV NJ (GMML) to the M48R M51R combined mutation significantly reduced cytopathic effects ( Fig. 6A-12 , 6A-14, B-12, and B-14). The reduced cytopathogenicity in BHK 21 cells and SH-SY5Y cells by the rVSV NJ mutants at 37°C was confirmed by the LDH assay ( Fig. 4B and D) . The M48R M51R mutant, GMM mutant, and GMML mutant of rVSV NJ had less of a CPE in SH-SY5Y cells than in BHK 21 cells. Temperature-sensitive mutants can be reverted back to wildtype VSV when the viruses are passaged many times. The tsO23 mutant was the most temperature-sensitive strain among the assembly-defective ts mutants, and it showed the least neurovirulence in mice when the ts M gene mutants were inoculated directly into the brain (27, 33) , which made the mutations in the tsO23 mutant preferable in our VSV vector for humans. When we injected mice intracranially with our rVSVs, the wild type and M gene mutants of rVSV Ind and rVSV NJ , mice injected with 1,000 infectious particles of rVSV Ind (WT) died within 4 days of injection. The strain with the single mutation at M51R, rVSV Ind (M51R), clearly more attenuated than the wild-type rVSV Ind , and two of three mice injected with the virus showed signs of distress (more than 20% weight loss) without paralysis; however, all survived the experiment. Mice injected with rVSV Ind with combined mutations M51R, G22E, and L111F in the M gene of rVSV Ind did not show any neurological dysfunction (Fig. 7D) . The combined mutations must have attenuated the VSV Ind much more effectively than the L111F mutation alone (27) and resulted in the complete loss of neurovirulence by rVSV Ind . Overall, the rVSV NJ strains were less virulent than the rVSV Ind strains in mice. Compared to rVSV Ind (WT), 1,000 infectious virus particles of rVSV N -J(WT) did not kill mice, but one mouse was paralyzed in both hind legs with injection of 1,000 infectious virus particles. None of the mutants of rVSV NJ , the M48R M51R mutant, GMM mutant, or GMML mutant, caused any neurological dysfunctions or distress in the mice. Comparatively less neuropathogenicity of rVSV NJ than rVSV Ind may be linked to the intrinsic ability of rVSV NJ to induce interferons (48) and the induction of interferons in brain by the rVSV NJ with M48R M51R mutations (49) .
One of the successful human vaccines that has a temperaturesensitive phenotype is the poliomyelitis vaccine (50) . Due to the sequential passages of the method used to develop the poliomyelitis vaccine, the genetic stabilities of the mutations were empirically proved. However, our ts M gene mutant, rVSV Ind (GML), was generated by the use of site-directed mutagenesis. The initial mutations were introduced by changing one nucleotide in an amino acid codon, and our concerns about the reversion of the rVSV to the wild-type phenotype had to be resolved. The genetic stability of the attenuated ts mutant vaccines should be tested and confirmed for use in humans. Our hypothesis that increasing the number of nucleotide changes in a codon for an amino acid in a mutation increases the genetic stability of the ts mutation was tested by changing all three nucleotides in a codon for the amino acid change. After 20 consecutive passages of rVSV Ind (GML)-New at 37°C, there were no nucleotide changes back to the wild-type amino acid codon ( Table 1 ), proving that additional nucleotide changes increased the stability of the mutation in vitro. Although further testing for the genetic stability of the mutation in animal hosts is still required, our results are promising to pursue further vaccination studies with our new rVSV Ind (GML) vector.
